The new ELISA test measures the interaction of a patented gain-of-function GPIb construction with von Willebrand factor in a patient sample.
The firm said that its metagenomic sequencing-based service provides a broad scope of pathogen testing for people with chronic medical conditions.
The firm said that its diagnostic instrument provides hematology results in six minutes, and it may speed time to patient treatments, as well as accelerate product sales.
Optrascan's CEO said he believes more pathologists will adopt digital technology when large capital expenditures are removed from the equation.
The company has started a clinical validation study for a PSA test running on the Claros 1 platform and expects to file for a PMA later this year.
The test expands the firm's Zika product pipeline, which also consists of a molecular assay authorized for emergency use.
The firm launched the service in part because it recognized that consumers increasingly prefer to pay for their healthcare services out of pocket and without having to get physician referrals.
2bPrecise is developing the needed ontology for its platform to enable clinicians to combine genomic and clinical data in their interactions with pediatric patients.
Industry executives said they believe ASRs are key components for laboratory directors who need to quickly develop critical diagnostic tests.
The company has recently launched its first diagnostic test on the market and is developing a second, which is currently in clinical trials.